Mateon Therapeutics, Inc. (MATN)
(Delayed Data from OTC)
$0.20 USD
-0.01 (-4.76%)
Updated May 3, 2019 02:44 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Oncotelic Therapeutics, Inc. [MATN]
Reports for Purchase
Showing records 1 - 19 ( 19 total )
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Light at End of Limbo Tunnel; Merger With Oncotelic
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Risk Profile on Already Speculative Thesis Hits Another Bump; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2017 Results; Cash Infusion Allows Next OXi4503 Cohort Dosing; Target Reduced to $0.55
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Thesis Reset: OXi4503 Running the Show Now; Target Reduced to $1
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Corrected - Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage of MATN shares to reallocate our research resources
Provider: Roth Capital Partners, Inc.
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Pathway to Registration Finally in FOCUS; Initiating with Buy
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Interim; First Smile; FOCUS Points in Right Direction; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Interim; First Smile; FOCUS Points in Right Direction; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
''4503 on Right Path; CA4P First FOCUS Interim Next Month; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
''4503 on Right Path; CA4P First FOCUS Interim Next Month; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
It''s All About "FOCUS" Grasshopper; Assuming Coverage at Buy; $2 PT
Provider: Rodman & Renshaw, Co.
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
It''s All About "FOCUS" Grasshopper; Assuming Coverage at Buy; $2 PT
Provider: H.C. Wainwright & Co., Inc.
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Transferring Coverage at Buy and $2 Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: Oncotelic Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Transferring Coverage at Buy and $2 Price Target
Provider: Rodman & Renshaw, Co.
|